Headlines about Osiris Therapeutics (NASDAQ:OSIR) have trended somewhat positive on Friday, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Osiris Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.4163026021661 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

TRADEMARK VIOLATION WARNING: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/13/osiris-therapeutics-osir-receiving-somewhat-favorable-media-coverage-study-shows.html.

About Osiris Therapeutics

Osiris Therapeutics, Inc is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing.

Insider Buying and Selling by Quarter for Osiris Therapeutics (NASDAQ:OSIR)

Receive News & Stock Ratings for Osiris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics Inc. and related stocks with our FREE daily email newsletter.